We investigated the association of survivin expression with prognosis and other apoptosis-related biological factors in 110 primary ovarian cancer patients admitted to the Division of Gynecologic ...

Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis ...

Survivin, an inhibitor of apoptosis protein, may be an attractive target for a variety of immunotherapeutic approaches for cancer, according to study results.Survivin is highly expressed by many ...

Survivin, a biomarker studied by researchers at Fox Chase Cancer Center, may help point out the patients who could respond to treatment.

Conclusions We conclude that increased expression of survivin is associated with adverse outcome in patients with primary breast cancer. These patients with high levels of survivin are potential ...

Background: Preoperative radiochemotherapy (RCT) is currently recommended in locally advanced rectal cancer with enhanced local control, higher sphincter preservation and decreased toxicity rates.

IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer 37% (7/19) patients experienced clinical ...

IMV Inc., a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that it will host a key opinion leader symposium on the role of survivin in cancer ...

Erlanger Health System announces registration is now open for the first ever Survivin’ and Thrivin’, a cancer survivorship symposium, to be held on Saturday, Sept. 17.